Jenscare Scientific Co., Ltd. (9877)

Overview

Jenscare Scientific Co., Ltd. is a pioneering medical device company that specializes in the research and development of cutting-edge invasive interventional therapies aimed at treating structural heart diseases. Established in 2011 and based in Ningbo, People's Republic of China, Jenscare Scientific has made significant strides in addressing some of the most challenging conditions affecting the heart’s structure. By focusing on innovative solutions for severe tricuspid regurgitation and aortic valve diseases, among others, the company targets a critical healthcare segment with a growing demand for minimally invasive treatments.

Products and Services

Jenscare Scientific Co., Ltd. is renowned for its commitment to developing advanced medical devices that offer new hope to patients with structural heart diseases. The company's notable product candidates include:

• LuX-Valve: A transcatheter tricuspid valve replacement (TTVR) product designed for patients suffering from severe tricuspid regurgitation who are at high surgical risk. The LuX-Valve represents a groundbreaking approach to treating this serious condition, providing a minimally invasive option to significantly improve patient outcomes and quality of life.
• Ken-Valve: Another leading-edge solution, the Ken-Valve is a transcatheter aortic valve replacement (TAVR) product candidate focused on treating patients with severe aortic regurgitation or those presenting with combined aortic stenosis. Its development underscores Jenscare's dedication to addressing a wide spectrum of structural heart diseases, offering a vital alternative to traditional surgical interventions.

Through these products, Jenscare Scientific Co., Ltd. showcases its expertise in leveraging advanced technologies to create viable treatment alternatives for complex heart conditions, emphasizing minimally invasive techniques. This not only positions the company at the forefront of the medical device industry in China but also significantly contributes to the global effort in improving patient care in the realm of structural heart diseases.